Robert W. Baird analyst Tristan Gerra maintained a Buy rating on Western Digital (WDC – Research Report) yesterday and set a price target of $55.00. The company’s shares closed last Friday at $47.09.
Gerra covers the Technology sector, focusing on stocks such as Intel, Nvidia, and Himax Technologies. According to TipRanks, Gerra has an average return of 11.1% and a 55.56% success rate on recommended stocks.
In addition to Robert W. Baird, Western Digital also received a Buy from Mizuho Securities’s Vijay Rakesh in a report issued on August 5. However, on the same day, Rosenblatt Securities maintained a Hold rating on Western Digital (NASDAQ: WDC).
See the top stocks recommended by analysts >>
The company has a one-year high of $69.99 and a one-year low of $41.63. Currently, Western Digital has an average volume of 3.5M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Western Digital Corp. engages in the development, manufacture, market and sale of data storage devices and solutions. It operates through the following product categories: client devices, data center devices and solutions, and client solutions. The client devices category includes mobile, desktop, gaming and digital video hard drives, solid state drives (SSDs), embedded products, and wafers. The data center devices and solutions category covers capacity and performance enterprise hard disk drives (HDDs), enterprise SSDs, data center software, and system solutions. The client solutions category offers removable products, hard drive content solutions, and flash content solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.
Read More on WDC:
- Amgen (AMGN) Receives a Hold from Mizuho Securities
- Analysts Are Bullish on These Technology Stocks: Ansys (ANSS), Spirit AeroSystems (SPR)
- Credit Suisse Reaffirms Their Hold Rating on Mayne Pharma Group Limited (MAYNF)
- Appen Ltd. (APPEF) Receives a Hold from Citigroup
- HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
